L. Åkerblom

发表

Antigen‐Specific Increases in the Number of Splenocytes Expressing MHC Class II Molecules Following Restimulation with Antigen in Various Physical Forms

C. Fossum, K. Lövgren, B. Morein, 1992, Scandinavian journal of immunology.

N-linked glycans in the CD4-binding domain of human immunodeficiency virus type 1 envelope glycoprotein gp160 are essential for the in vivo priming of T cells recognizing an epitope located in their vicinity.

A. Sjölander, S. Olofsson, S. Sjölander, 1996, Virology.

Vaccine protection against HIV-2 infection in cynomolgus monkeys.

J. Albert, E. Norrby, G. Wadell, 1991, AIDS research and human retroviruses.

Cross-neutralizing antibodies to HIV-1 in mice after immunization with gp160 iscoms. Dissection of the immune response.

P. Nara, B. Morein, L. Åkerblom, 1991, AIDS research and human retroviruses.

A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization

E. Norrby, B. Wahrén, J. Hinkula, 1990, Journal of virology.

Do Biological Medicinal Products Pose a Risk to the Environment?

T. Kühler, L. Åkerblom, G. Carlin, 2009, Drug safety.

Detection of porcine MHC class II antigens in different immunoassays.

C. Fossum, U. Magnusson, L. Åkerblom, 1991, Zentralblatt fur Veterinarmedizin. Reihe B. Journal of veterinary medicine. Series B.

Immunization with recombinant modified vaccinia virus Ankara can modify mucosal simian immunodeficiency virus infection and delay disease progression in macaques.

J. Heeney, G. Sutter, C. Nilsson, 2002, The Journal of general virology.

HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates.

T. Lehner, J. Heeney, R. Wagner, 1999, Immunology letters.

The role of type‐1 and type‐2 T‐helper immune responses in HIV‐1 vaccine protection

J. Heeney, D. Davis, B. Morein, 1998, Journal of medical primatology.

beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques.

T. Lehner, J. Heeney, Y. Wang, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines.

J. Heeney, M. Dings, L. Åkerblom, 1994, Vaccine.

Identification of amino acids in the V3 region of gp120 critical for virus neutralization by human HIV-1-specific antibodies.

E. Norrby, B. Wahrén, B. Mäkitalo, 1991, Immunology.

A recombinant prime, peptide boost vaccination strategy can focus the immune response on to more than one epitope even though these may not be immunodominant in the complex immunogen.

J. Heeney, D. Davis, B. Morein, 1997, Vaccine.

A colorimetric reverse transcriptase assay optimized for Moloney murine leukemia virus, and its use for characterization of reverse transcriptases of unknown identity.

M. Bendinelli, D. Matteucci, J. Gronowitz, 1998, Journal of virological methods.

Initiation of Immune Response with ISCOM

M. Villacrés-Eriksson, B. Morein, L. Åkerblom, 1993 .

Identification of two antigenically and genetically distinct lineages of H3N8 equine influenza virus in Sweden

T. Linné, L. Åkerblom, L. Oxburgh, 1998, Epidemiology and Infection.

Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp160 of HIV-1.

R. Redfield, D. Birx, E. Sandström, 1993, Journal of acquired immune deficiency syndromes.

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

J. Heeney, A. Borsetti, A. Caputo, 1999, Nature Medicine.

Challenges with advanced therapy medicinal products and how to meet them

Robert Zorec, Balázs Sarkadi, Sophie Lucas, 2010, Nature Reviews Drug Discovery.

Immune response to immunostimulatory complexes (ISCOMs) prepared from human immunodeficiency virus type 1 (HIV-1) or the HIV-1 external envelope glycoprotein (gp120).

L. Arthur, J. Bess, S. Pyle, 1989, Vaccine.

Improvement and development of rapid chromatographic strip-tests for the diagnosis of rinderpest and peste des petits ruminants viruses.

L. Åkerblom, A. Brüning-Richardson, B. Klingeborn, 2011, Journal of virological methods.

Development of a rapid chromatographic strip test for the pen-side detection of foot-and-mouth disease virus antigen.

S. Reid, L. Åkerblom, N. Ferris, 2001, Journal of virological methods.

Presentation of a foreign peptide on the surface of tomato bushy stunt virus.

B. Strandberg, K. Tomenius, P. Oxelfelt, 1997, The Journal of general virology.

Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape.

J. Hansen, J. Nielsen, A. Sönnerborg, 1993, The Journal of general virology.

Monoclonal antibodies to native HIV type 1 reverse transcriptase and their interaction with enzymes from different subtypes.

J. Albert, T. Unge, J. Gronowitz, 2000, AIDS research and human retroviruses.

Characterization of immunostimulating complexes (ISCOMS) of HIV-1.

M. Ozel, L. Arthur, S. Höglund, 1990, Viral immunology.

Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response.

J. Hansen, S. Olofsson, S. Sjölander, 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Adjuvanticity of ISCOMs incorporating a T cell-reactive lipoprotein of the facultative intracellular pathogen Francisella tularensis.

I. Golovliov, A. Tärnvik, A. Sjöstedt, 1995, Vaccine.

Neutralization of primary HIV-1 SF13 can be detected in extended incubation phase assays with sera from monkeys immunized with recombinant HIV-1 SF2 gp120.

J. Heeney, G. Vanham, S. Barnett, 2004, Vaccine.

Serological responses in cats vaccinated with FeLV ISCOM and an inactivated FeLV vaccine.

A. Osterhaus, O. Jarrett, B. Morein, 1989, Vaccine.

Formation and characterization of FeLV ISCOMs.

A. Osterhaus, B. Morein, L. Åkerblom, 1989, Vaccine.

Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 iscom vaccine.

F. Chiodi, E. Norrby, K. Lövgren, 1994, Journal of acquired immune deficiency syndromes.

Mechanisms behind the immune response induced by immunostimulating complexes.

A. Sjölander, K. Lövgren, B. Rönnberg, 1994, AIDS research and human retroviruses.

Carbohydrate determinant NeuAc-Gal beta (1-4) of N-linked glycans modulates the antigenic activity of human immunodeficiency virus type 1 glycoprotein gp120.

J. Hansen, S. Olofsson, E. Sjögren-Jansson, 1992, The Journal of general virology.

Induction of homologous virus neutralizing antibodies in guinea-pigs immunized with two human immunodeficiency virus type 1 glycoprotein gp120-iscom preparations. A comparison with other adjuvant systems.

J. Hansen, S. Sjölander, B. Morein, 1996, Vaccine.

The HIV-1 V3 domain on field isolates: participation in generation of escape virus in vivo and accessibility to neutralizing antibodies

J. Hansen, J. Nielsen, M. Arendrup, 2005, Archives of Virology.

Sequence and expression of a membrane-associated C-type lectin that exhibits CD 4-independent binding of human immunodeficiency virus envelope glycoprotein gpl 20 ( virus receptor / type UI membrane protein / mannose binding )

S. Olofsson, S. Jeansson, L. Åkerblom, 2022 .

Neutralizing cross‐reactive and non‐neutralizing monoclonal antibodies to HIV‐1 gp 120

B. Wahrén, B. Morein, B. Mäkitalo, 1990, AIDS.

Use of not authorised stem-cell based products: The Committe for Advanced Therapies (CAT) perspective

M. Vassiliou, I. Reischl, D. Niederwieser, 2010 .